Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **gastrointestinal epithelial barrier** is not a single molecular target but rather an integrated physiological system formed primarily by sheets of tightly joined epithelial cells lining the digestive tract. This structure serves as a critical interface between the body and potentially harmful luminal contents—including toxins, pathogens, and antigens—while allowing selective absorption of nutrients and water. The integrity of this barrier depends on several components: *Physical elements*: Tight junctions between adjacent cells regulate paracellular transport; specialized cell types such as goblet cells secrete mucus that forms an additional protective layer over the epithelium; commensal microbiota contribute both directly and indirectly to maintaining homeostasis. *Immune elements*: Underlying immune cells provide surveillance against invading pathogens while limiting unnecessary inflammation. Disruption or dysfunction of this complex system has been implicated in numerous diseases including inflammatory bowel disease, irritable bowel syndrome, food allergies, metabolic syndrome/diabetes, infections, celiac disease, non-alcoholic fatty liver disease, among others. While therapies such as probiotics or zinc supplementation may help restore normal function in certain contexts by enhancing tight junction integrity or modulating immune responses/microbiota composition,[1][2][3][4][5] "gastrointestinal epithelial barrier function" itself does not refer to a discrete druggable target like an enzyme or receptor—it describes an emergent property arising from multiple cellular components working together.[1] Therefore it should be classified as *not* being a canonical therapeutic target molecule/receptor.
Probiotics—modulate gut microbiota, improve tight junction integrity, reduce inflammation, restore mucus layer function[5] Zinc—may enhance tight junction protein expression and reduce permeability in some contexts[2]
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gastrointestinal epithelial barrier function.